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Introduction
There is growing evidence that chronic 
exposure to inorganic As (iAs) may increase 
the risk of cardiometabolic (CM) disor-
ders, including diabetes mellitus (DM) and 
cardiovascular diseases (CVD) (Kuo et al. 
2013; Maull et al. 2012; Moon et al. 2012). 
Experimental studies report adverse effects of 
iAs and its metabolites on mechanisms associ-
ated with CM disorders, such as insulin secre-
tion and signaling, lipid metabolism, systemic 
inflammation, and atherosclerosis (Cheng 
et al. 2011; Douillet et al. 2013; Druwe et al. 
2012; Fu et al. 2010; Lemaire et al. 2011; 
Muthumani and Prabu 2014; Paul et al. 2007). 
Recent reviews of the epidemiological litera-
ture suggest that exposure to levels of iAs in 
drinking water > 150 μg As/L may increase 
the risk of diabetes (Maull et al. 2012) and 
CVD outcomes (Abhyankar et al. 2012; Moon 
et al. 2012; Navas-Acien et al. 2005). Evidence 
of relationships at low to moderate levels of 
exposure is more limited and equivocal.
To date, few epidemiologic studies have 
examined associations between moderate iAs 
exposure and markers of CM risk. Such studies 
may help to provide insight into the potential 
role of iAs exposure in the development and 
progression of CVD and diabetes. A few studies 
in industrially contaminated areas, or in settings 
with mean water As concentrations > 150 μg/L, 
have reported As exposure to be associated with 
CM markers such as elevated blood pressure 
and elevated fasting glucose, triglyceride, and 
low-density lipoprotein (LDL) cholesterol levels 
(Chen et al. 2012; Karim et al. 2013; Wang 
et al. 2007). However, there are limited and 
inconsistent data on associations with CM risk 
markers, most notably dyslipidemias, at lower 
As exposures (Abhyankar et al. 2012; Gribble 
et al. 2012; Jones et al. 2011).
Evidence is also limited regarding the role 
of iAs metabolism in determining health risks 
associated with iAs exposure. In humans, iAs 
is enzymatically methylated to yield methyl- 
arsenic (MAs) and subsequently dimethyl-
arsenic (DMAs) metabolites that are, along 
with residual iAs, excreted mainly in urine 
(Thomas et al. 2007). Urinary As profiles 
characterized by low percentages of DMAs 
and high percentages of MAs are thought to 
indicate a low capacity to methylate iAs. These 
indicators have been linked to an increased 
risk of cancer and precancerous skin lesions 
(Ahsan et al. 2007; Chen et al. 2003a, 2003b; 
Pierce et al. 2013; Yu et al. 2000). However, 
the relationship between urinary profiles of 
iAs metabolites and non-cancerous outcomes 
remains unclear (Chen et al. 2013b; Del Razo 
et al. 2011; Huang et al. 2007; Kim et al. 
2013; Nizam et al. 2013).
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Background: Exposure to arsenic (As) concentrations in drinking water > 150 μg/L has been 
associated with risk of diabetes and cardiovascular disease, but little is known about the effects of 
lower exposures.
oBjective: This study aimed to examine whether moderate As exposure, or indicators of individual 
As metabolism at these levels of exposure, are associated with cardiometabolic risk.
Methods: We analyzed cross-sectional associations between arsenic exposure and multiple markers 
of cardiometabolic risk using drinking-water As measurements and urinary As species data obtained 
from 1,160 adults in Chihuahua, Mexico, who were recruited in 2008–2013. Fasting blood glucose 
and lipid levels, the results of an oral glucose tolerance test, and blood pressure were used to char-
acterize cardiometabolic risk. Multivariable logistic, multinomial, and linear regression were used 
to assess associations between cardiometabolic outcomes and water As or the sum of inorganic and 
methylated As species in urine.
results: After multivariable adjustment, concentrations in the second quartile of water As (25.5 
to < 47.9 μg/L) and concentrations of total speciated urinary As (< 55.8 μg/L) below the median 
were significantly associated with elevated triglycerides, high total cholesterol, and diabetes. 
However, moderate water and urinary As levels were also positively associated with HDL choles-
terol. Associations between arsenic exposure and both dysglycemia and triglyceridemia were higher 
among individuals with higher proportions of dimethylarsenic in urine.
conclusions: Moderate exposure to As may increase cardiometabolic risk, particularly in indi-
viduals with high proportions of urinary dimethylarsenic. In this cohort, As exposure was associated 
with several markers of increased cardiometabolic risk (diabetes, triglyceridemia, and cholesterol-
emia), but exposure was also associated with higher rather than lower HDL cholesterol.
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This cross-sectional study explored asso-
ciations between CM risk and chronic exposure 
to iAs in a recently established cohort of 
adult residents of Chihuahua (Mexico) who 
consume water with a wide range of iAs 
concentrations. We examined the relation-
ship between iAs in drinking water and urine; 
we also investigated the relationship between 
urinary indicators of iAs metabolism and CM 
risk based on measurements of dysglycemia, 
including diabetes, dyslipidemia, and blood 
pressure levels.
Materials and Methods
The Chihuahua cohort. All procedures involving 
human subjects were approved by institutional 
review boards at the University of North 
Carolina at Chapel Hill and Cinvestav-IPN 
(Centro de Investigación y de Estudios 
Avanzados del Instituto Politécnico Nacional, 
Mexico City, Mexico). All participants provided 
signed informed consent. A total of 1,160 
adults (≥ 18 years old) with a minimum 5-year 
uninterrupted residency in the study area were 
recruited in household visits between 2008 and 
2012. The participation rate was 67%. Other 
exclusion criteria were pregnancy, self-reported 
kidney or urinary tract infection (both condi-
tions that affect profiles of iAs metabolites in 
urine), and potential occupational exposure to 
As (e.g., working with pesticides or in mines 
or smelters). Samples of drinking water were 
obtained from the participants’ households. 
An interviewer-administered study question-
naire was used to record data on residency, 
occupation, drinking-water sources and use, 
smoking, alcohol consumption, and medical 
history. As described previously (Currier et al. 
2014), spot urine and fasting venous blood 
were collected during a morning medical 
examination that included an oral glucose 
tolerance test with blood drawn 2 hr after a 
75-g glucose dose. Plasma from both fasting 
and 2-hr blood samples was stored at –80°C 
until analysis. Urine samples were aliquoted 
and immediately frozen. Trained staff obtained 
measurements of participants’ weight (without 
shoes and in light clothing) to the nearest 
0.1 kg and measurements of their height to 
the nearest 0.1 cm; this information was used 
to calculate the body mass index (BMI) of the 
participants. BMI cutoffs of ≥ 25.0, ≥ 30, and 
< 18.5 kg/m2 were used to define overweight, 
obese, and underweight individuals, respec-
tively (World Health Organization [WHO] 
Expert Committee on Physical Status 1995). 
Participants’ waist circumference was measured 
at the midpoint between the lowest rib and the 
iliac crest. Blood pressure was assessed using a 
manual sphygmomanometer. Three measure-
ments were taken at intervals of at least 1 min, 
with a 5-min rest before obtaining the first 
reading; the mean of the last two measurements 
was used. Participants were seated with their 
backs supported, feet on the floor, and the arm 
supported in a horizontal position, with the cuff 
at the level of the heart.
Arsenic analyses. Hydride generation-
atomic absorption spectrometry coupled 
with a cryotrap (HG-CT-AAS) (Hernández-
Zavala et al. 2008) was used to determine the 
concentration of As in drinking water and the 
Table 1. Characteristics of the sample by concentration of arsenic in household water. 
Characteristic All participants
Household water arsenic quartiles (μg/L) 
< 25.5 ≥ 25.5 to < 47.9 ≥ 47.9 to < 79.0 ≥ 79.0
Total n 1,038 260 260 259 259
Sociodemographic, lifestyle
Age, years* 45.6 ± 15.9 47.4 ± 16.8 43.4 ± 16.4 44.6 ± 14.5 47.0 ± 15.4
Female 712 (68.6) 180 (69.2) 174 (66.9) 185 (71.4) 173 (66.8)
Higher than primary education* 320 (30.8) 93 (35.8) 106 (40.8) 71 (27.4) 50 (19.3)
Smokes 291 (28.0) 65 (25.0) 71 (27.6) 70 (27.0) 85 (32.8)
Drinks alcohol** 423 (40.8) 90 (34.6) 114 (43.9) 115 (44.4) 104 (40.2)
Recent seafood intake** 260 (25.1) 79 (30.4) 64 (24.6) 64 (24.7) 53 (20.5)
Anthropometric, cardiometabolic
Weight statusa**
Overweight 368 (35.5) 91 (35.0) 88 (33.9) 87 (33.6) 102 (39.4)
Obese 411 (39.6) 92 (35.4) 112 (43.1) 118 (45.6) 89 (34.4)
Waist circumference, cm
Female** 98.8 (13.0) 96.2 (12.0) 100.7 (12.9) 100.1 (14.5) 98.2 (12.1)
Male 96.7 (12.1) 97.7 (11.8) 96.5 (12.0) 97.0 (12.3) 95.6 (12.2)
Dysglycemiab
Diabetes 183 (17.6) 33 (12.7) 53 (20.4) 47 (18.2) 50 (19.3)
Prediabetes 156 (15.0) 41 (15.8) 37 (14.2) 38 (14.7) 40 (15.4)
Triglycerides ≥ 150 mg/dL* 412 (41.0) 85 (33.5) 104 (41.4) 110 (43.8) 113 (45.6)
Total cholesterol ≥ 200 mg/dL** 234 (23.3) 44 (17.3) 61 (24.3) 67 (26.7) 62 (25.0)
LDL cholesterol ≥ 130 mg/dLc 160 (16.3) 33 (13.2) 43 (17.4) 45 (18.5) 39 (16.3)
HDL < 40/50 mg/dL** 589 (58.7) 161 (63.4) 151 (60.1) 144 (57.4) 133 (53.6)
Hypertensiond 439 (42.3) 106 (40.8) 106 (40.8) 109 (42.1) 118 (45.6)
Urinary As and dilution markers
Total Ase (μg/L)* 55.8 (27.1–105) 22.9 (6.5–48.3) 59.0 (35.4–94.3) 62.6 (33.4–101) 96.6 (52.0–150)
DMAs (μg/L)* 42.4 (20.5–77.6) 16.2 (5.1–35.0) 44.0 (26.3–71.7) 62.6 (33.4–101) 96.6 (52.0–150)
MAs (μg/L)* 7.7 (3.2–14.9) 2.7 (0.8–7.3) 8.3 (4.5–13.5) 47.5 (25.9–77.5) 69.5 (38.5–115)
iAs (μg/L)* 5.0 (1.9–10.0) 1.5 (0.5–4.8) 5.7 (2.7–9.3) 8.7 (4.4–14.4) 13.5 (6.0–24.0)
DMAs/MAs 5.5 (4.0–7.4) 5.6 (4.1–7.5) 5.7 (4.2–7.6) 5.4 (4.1–7.4) 5.3 (3.8–7.1)
MAs/iAs 1.6 (1.2–2.1) 1.6 (1.1–2.3) 1.5 (1.1–2.0) 1.6 (1.2–2.1) 1.6 (1.2–2.0)
Percent DMAs 76.8 (70.6–81.5) 76.7 (70.3–81.0) 76.6 (71.3–81.3) 77.2 (71.6–82.8) 76.6 (69.6–81.2)
Percent MAs 14.0 (10.9–17.7) 13.9 (10.8–17.3) 13.5 (10.5–1.37) 14.2 (11.1–17.7) 14.4 (11.2–18.4)
Percent iAs 8.9 (6.4–12.3) 8.8 (6.0–12.9) 9.4 (6.4–12.8) 8.5 (6.4–11.6) 8.9 (6.7–12.1)
Creatinine, mg/dL* 135 (74.7–173) 115 (60–162) 131 (78–190) 140 (80–183) 144 (82–167)
Data are n (%), mean ± SD, or median (25th–75th percentile) unless otherwise indicated. One-way analysis of variance (ANOVA), Pearson’s chi-square, or Kruskal–Wallis test for 
differences across increasing quartiles of water As. Distributions among individuals with household water As, n = 1,038 for all variables except LDL (n = 980) and other lipids (n = 1,004).
aWeight status: BMI ≥ 25 to < 30 overweight, BMI ≥ 30 obese. bDiabetes: fasting plasma glucose (FPG) ≥ 126 mg/dL, 2-hr plasma glucose (2HPG) ≥ 200 mg/dL, or self-reported diabetes 
diagnosis or medication use. Prediabetes: FPG ≥ 110 to < 126 mg/dL or 2HPG ≥ 140 mg/dL. cLDL cholesterol: estimated using the Friedewald equation if triglycerides < 400 mg/dL 
(Oliveira et al. 2013). dHypertension: SBP > 140 mmHg, DBP > 90 mmHg or anti-hypertensive medication use [medication use reported by n = 126 (28.7%) of the hypertensive individuals]. 
eTotal speciated urinary arsenic: Σ[dimethylated (DMAs), monomethylated (MAs), and inorganic (iAs) arsenic species]. *p < 0.05; **p < 0.10.
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concentrations of inorganic and methylated As 
species in urine. Arsenobetaine, arseno choline, 
and arsenosugars cannot be measured using this 
method. A certified standard reference material, 
Arsenic Species in Frozen Human Urine (SRM 
2669; National Institute of Standards and 
Technology, Gaithersburg, MD) was used to 
ensure accuracy. Concentrations of As species 
measured in SRM 2669 by HG-CT-AAS 
ranged from 86.7 to 106.4% of the certified 
values. The limit of detection (LOD) for As 
in water as well as for As species in urine was 
0.01 μg As/L. The concentration of creatinine 
in urine was determined using a colorimetric 
assay (Cayman Chemical Company, Ann 
Arbor, MI). Concentrations of water As and 
urinary As species below the LOD (1.9% for 
water As, 1.6% for urinary iAs) were imputed 
at LOD/2. Total speciated As in urine (tAs) 
was calculated as the sum of iAs, MAs, and 
DMAs. The pattern of iAs metabolism was 
characterized using the percentage of tAs 
present as DMAs, MAs, and iAs and the ratios 
of MAs/iAs and DMAs/MAs.
CM risk markers. A Prestige 24i Chemistry 
Analyzer (Tokyo Boeki Medisys Inc., Tokyo, 
Japan) was used to determine fasting plasma 
glucose (FPG) and 2-hr plasma glucose 
(2HPG) concentrations, in addition to 
triglyceride (TG), total cholesterol (TC), and 
high-density lipoprotein cholesterol (HDL) 
concentrations in fasting plasma. Reference 
human sera (Serodos and Serodos PLUS; 
Human Diagnostics Worldwide) were used 
for quality control. LDL was calculated using 
the Friedewald equation; 28 individuals with 
measured lipids outside accepted ranges for this 
approach were excluded from this calculation 
(Oliveira et al. 2013). Diabetes was classified 
by FPG ≥ 126 mg/dL, 2HPG ≥ 200 mg/dL, 
or self-reported diabetes diagnosis or medica-
tion use (WHO/International Diabetes 
Federation 2006). Prediabetes was defined as 
the absence of diabetes with FPG ≥ 110 mg/
dL or 2HPG ≥ 140 mg/dL. Individuals with 
diabetes or prediabetes were classified as having 
dysglycemia. Elevated fasting levels of each lipid 
were defined as plasma TG ≥ 150 mg/dL, TC 
≥ 200 mg/dL, and LDL ≥ 130 mg/dL (Miller 
et al. 2011; National Cholesterol Education 
Program 2002). Fasting HDL < 40 mg/dL in 
men and < 50 mg/dL in women were desig-
nated as low. Hypertension was defined by 
systolic blood pressure (SBP) > 140 mmHg, 
diastolic blood pressure (DBP) > 90 mmHg, or 
self-reported use of anti-hypertensive medication 
(Chobanian et al. 2003).
Statistical analysis. Associations between 
iAs exposure and each CM risk marker were 
analyzed using both categorical and continuous 
exposure measures. Arsenic concentrations in 
water and urine, as well as urinary DMAs/MAs 
and MAs/iAs ratios, were either categorized 
in quartiles or were natural log–transformed 
when used as continuous measures to make 
their distributions more normal. Associations 
with the percentage of urinary tAs comprised 
by DMAs, MAs, and iAs were presented as 
quartiles or dichotomized at the median. 
Chi-square, ANOVA, and Kruskal–Wallis 
tests were used as appropriate to determine 
the significance of differences in subject 
 characteristics by level of iAs exposure.
Multinomial (diabetes and prediabetes vs. 
neither) or simple logistic regression models 
(other variables) were used to analyze associa-
tions between iAs exposure and each CM risk 
outcome. To evaluate associations at various 
exposure doses, both categorical and log-
transformed continuous exposure variables were 
used. Models were adjusted for age, sex, educa-
tion, ethnicity, smoking, alcohol consumption, 
waist circumference, BMI, primary source of 
household drinking water (wells, treatment 
plants, and other), and self-reported seafood 
intake in the past week (a potential source of 
arsenobetaine or arsenosugars). Supplementary 
models examined the effects of adjusting for 
log-transformed urinary creatinine concentra-
tions as recommended (Maull et al. 2012) or 
of normalizing As concentrations by dividing 
by the concentration of urinary creatinine. 
Statistical significance of main effects was set 
at p < 0.05 with p < 0.10 indicating marginal 
significance. Product terms (continuous 
outcomes) or relative excess risk for interac-
tion (categorical outcomes) were calculated to 
assess inter actions (p < 0.10) when exploring 
combined effects of iAs exposure and metabo-
lism (Vanderweele and Knol 2014). Thus, 
all interactions were evaluated on an additive 
scale. The primary analysis sample (n = 1,090, 
94%) excluded individuals with missing data 
(n = 70 for urinary tAs, blood pressure, dysgly-
cemia, or covariates); 37 additional individuals 
were missing lipid measurements (n = 1,053). 
Water As measurements were unavailable for 
an additional 52 participants in the analysis 
sample (n = 1,038; 1,004 for lipids). Multiple 
imputations fit using 10 replicates of chained 
equations indicated that the results of the 
complete case analysis did not differ signifi-
cantly when missing data were imputed (data 
not shown). All analyses used STATA version 
13.1 (StataCorp; College Station, TX).
Results
As exposure. Sociodemographic and anthropo-
metric characteristics of the Chihuahua cohort, 
as well as data characterizing CM risk preva-
lence, iAs exposure, and urinary iAs metabolites 
are provided in Table 1. Concentrations of As in 
drinking water ranged from below the LOD to 
419.8 μg/L, with a median of 47.9 μg/L. A total 
of 83.3% of the analysis sample exceeded the 
U.S. Environmental Protection Agency (EPA) 
and WHO recommended limit of 10 μg As/L, 
and 75.3% of the analysis sample exceeded 
the limit in Mexico of 25 μg As/L (Dirección 
General de Normas 1994; U.S. EPA 2014). 
Concentrations of total speciated urinary As 
(tAs) ranged from 0.52 to 491.5 μg/L, with a 
median of 55.8 μg/L. DMAs was the major 
metabolite (median 76.8% of tAs), followed 
by MAs (14.0%) and iAs (8.9%). Urinary tAs 
(Table 1) and concentrations of each As species 
increased with increasing concentrations of 
water As. However, the percentages of MAs and 
iAs increased with increasing amounts of urinary 
tAs (see Supplemental Material, Table S1). 
Water As and urinary tAs were correlated 
(Spearman’s rho = 0.47).
Water As and CM risk. Overall, 18% of 
the study participants had diabetes (115 of 
183 reporting previous diagnosis), and 15% 
had prediabetes (Table 1). Forty-one percent 
had elevated TG, 23% had high TC, 16% had 
high LDL, and 42% had hypertension.
In mult ivar iable-adjusted models 
(Table 2), drinking water As was associated 
Table 2. Household drinking water arsenic concentrations and prevalent cardiometabolic risk outcomes: 
odds ratios (95% CI).
Cardiometabolic outcome
Water arsenic exposure quartile (μg/L)
ln-Water As (μg/L)≥ 25.5 to < 47.9 ≥ 47.9 to < 79.0 ≥ 79.0
Dysglycemiaa
Diabetes 2.46 (1.44, 4.21)* 1.74 (1.01, 2.99)* 1.65 (0.97, 2.81)** 1.14 (1.05, 1.25)*
Prediabetes 1.14 (0.68, 1.91) 1.04 (0.62, 1.73) 1.13 (0.68, 1.88) 1.00 (0.94, 1.09)
Triglycerides ≥ 150 mg/dL 1.45 (0.99, 2.14)** 1.53 (1.04, 2.24)* 1.69 (1.15, 2.49)* 1.09 (1.03, 1.15)*
Total Cholesterol ≥ 200 mg/dL 1.75 (1.11, 2.74)* 1.89 (1.21, 2.95)* 1.65 (1.05, 2.59)* 1.08 (1.01, 1.16)*
LDL ≥ 130 mg/dLb 1.54 (0.92, 2.56)** 1.59 (0.96, 2.65)** 1.35 (0.80, 2.27) 1.04 (0.96, 1.12)
HDL < 40/50 mg/dL 0.78 (0.52, 1.17) 0.63 (0.42, 0.93)* 0.59 (0.40, 0.88)* 0.87 (0.82, 0.93)*
Hypertensionc 1.30 (0.84, 2.00) 1.27 (0.82, 1.94) 1.41 (0.91, 2.17) 1.03 (0.97, 1.10)
Results are derived from multinomial or logistic models adjusted for age, sex, education, smoking status, alcohol 
consumption, recent seafood intake, weight status, elevated waist circumference, and main water source (well, treat-
ment plant, or other); multinomial models used for diabetes and prediabetes versus neither; logistic models used for other 
outcomes. aDiabetes: fasting plasma glucose (FPG) ≥ 126 mg/dL, 2-hr plasma glucose (2HPG) ≥ 200 mg/dL, or self-reported 
diabetes diagnosis or medication use. Prediabetes: FPG ≥ 110 to < 126 mg/dL or 2HPG ≥ 140 mg/dL. Normoglycemic 
individuals (i.e., individuals with no diabetes or prediabetes) are the referent. bLDL-cholesterol: estimated using the 
Friedewald equation if triglycerides < 400 mg/dL (Oliveira et al. 2013). cHypertension: SBP > 140, DBP > 90, or use of anti-
hypertensive medication (medication use reported by 27.9% of hypertensive individuals). Normotensive individuals (no 
stage 1 or 2 hypertension) are the referent. 
*p < 0.05, **p < 0.10 for odds ratios for elevated versus low cardiometabolic risk associated with increasing water As 
exposure versus the lowest quartile (< 25.5 μg/L). 
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with several markers of CM risk, including 
elevated TC and TG, as well as with diabetes 
(p < 0.05 for log water As), with increased 
risk in the second quartile (≥ 25.5 μg As/L) 
and no evidence of further increases in risk 
at higher exposures. However, greater expo-
sures to water As were associated with reduced 
odds of low HDL, with patterns suggesting 
a monotonic dose–response curve (p < 0.05). 
Excluding individuals with diabetes (n = 183) 
did not significantly affect relationships 
with other outcomes associated with water 
As [adjusted ORs for log-transformed water 
As were 1.07 (95% CI: 1.01, 1.14) for TG, 
1.07 (95% CI: 1.00, 1.15) for TC, and 0.87 
(95% CI: 0.82, 0.93) for HDL].
Associations with continuous CM 
measurements are shown in the Supplemental 
Material, Table S2. Although water As was 
not associated with prediabetes (Table 2), 
increasing exposure was associated with 
elevated mean FPG and 2HPG among 
individuals not using diabetes medications 
and among individuals without diabetes (see 
Supplemental Material, Table S2). After 
multivariable adjustment, increasing concen-
trations of water As were also associated with 
significant increases in mean FPG and 2HPG 
among fully normoglycemic participants (i.e., 
individuals without either diabetes or predia-
betes; Figure 1). Consistent with the categor-
ical outcomes, after adjustment, increasing 
concentrations of water As were associated 
with increases in mean TG and TC and 
decreases in mean HDL, but not with mean 
LDL. Water As was not associated with mean 
DBP; the association with SBP was attenuated 
when individuals with diabetes were excluded 
(see Supplemental Material, Table S2).
Urinary tAs and CM risk. Urinary tAs 
concentrations were associated with multiple 
markers of CM risk. Similarly to the findings 
for water As, increasing concentrations of 
urinary tAs were associated with increased odds 
of diabetes and elevated TG, and there was 
evidence of increased risk at moderate concen-
trations (≥ 27.1 to < 55.8 μg/L) (Table 3). The 
highest quartile of tAs (≥ 105 μg/L) was associ-
ated with elevated TC (p < 0.05). There were, 
however, reduced odds of low HDL associated 
with log tAs (p < 0.05). Additional adjust-
ment for urinary creatinine and urinary tAs 
metabolite composition (Table 3) tended to 
strengthen the magnitude of the associations. 
Similarly to water As, urinary tAs was not asso-
ciated with prediabetes, but it was associated 
with significant increases in mean FPG among 
normoglycemic individuals in multivariable 
adjusted models (Figure 1); the highest quartile 
of tAs was also associated with mean increases 
in 2HPG. Excluding individuals with diag-
nosed diabetes did not meaningfully influence 
relationships between urinary tAs and other 
outcomes [adjusted ORs for the highest vs. 
lowest quartiles: 1.71 (95% CI: 1.08, 2.71) 
for high TG, 2.14 (95% CI: 1.26, 3.62) for 
high TC, and 0.71 (95% CI: 0.44, 1.12) 
for low HDL].
The relationships with continuous CM 
markers after multivariable adjustment (see 
Supplemental Material, Table S2) were 
similar to those with categorical outcomes, 
with urinary tAs positively associated with 
TG, TC, HDL, and FPG, as well as with 
2HPG in subjects not using medications to 
control the levels of those markers. Among 
individuals without diabetes, associations 
with 2HPG were attenuated. Urinary tAs 
was not associated with SBP or DBP even 
when normalized to creatinine [coefficients 
Figure 1. Adjusted mean (95% CI) difference in fasting or 2-hr plasma glucose associated with As 
exposure among normoglycemic subjects. Adjusted mean (95% CI) difference in glucose measurement 
for increasing quartiles of water As or total speciated urinary As relative to individuals in the lowest 
quartile (< 25.5 μg/L for water and < 27.1 μg/L for urine). Estimated from linear regression models including 
age, sex, education, ethnicity, weight status, waist circumference, smoking status, alcohol consumption, 
recent seafood intake, and water source (well, treatment plant, or other). Urinary As models were addi-
tionally adjusted for urinary creatinine and ≥ median %DMAs, MAs, and iAs. Models excluded individuals 
with 2-hr plasma glucose > 140 mg/dL, fasting plasma glucose > 110 mg/dL, or diagnosed diabetes. Among 
normoglycemic subjects: n in each quartile of water As 1 = 186, 2 = 170, 3 = 174, 4 = 169; of urinary As: 
1 = 195, 2 = 181, 3 = 186, 4 = 170.
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Table 3. Total speciated urinary As and prevalent cardiometabolic risk: odds ratios (95% CIs).
Cardiometabolic outcome
Total urinary speciated arsenic quartiles (μg/L) ln-Total urinary As 
(μg/L)≥ 27.1 to < 55.8 ≥ 55.8 to <105.0 ≥ 105.0
n 272 273 272 —
Multivariable adjusted
Dysglycemiaa
Diabetes 1.57 (0.94, 2.63)** 1.56 (0.92, 2.65)** 1.99 (1.19, 3.33)* 1.29 (1.09, 1.53)*
Prediabetes 0.92 (0.56, 1.53) 1.21 (0.74, 1.98) 1.15 (0.69, 1.92) 1.04 (0.89, 1.23)
Triglycerides ≥ 150 mg/dL 1.39 (0.95, 2.02)** 1.47 (1.01, 2.13)* 1.80 (1.23, 2.64)* 1.23 (1.08, 1.39)*
Cholesterol ≥ 200 mg/dL 1.15 (0.74, 1.78) 1.35 (0.88, 2.07) 1.54 (1.00, 2.38)* 1.15 (1.00, 1.33)*
LDL ≥ 130 mg/dLb 0.99 (0.60, 1.62) 1.22 (0.75, 1.99) 1.25 (0.76, 2.05) 1.09 (0.93, 1.28)
HDL < 40/50 mg/dL 0.94 (0.64, 1.27) 1.09 (0.74, 1.60) 0.82 (0.56, 1.21) 0.82 (0.72, 0.93)*
Hypertensionc 0.67 (0.44, 1.01)* 0.60 (0.40, 0.92)* 0.77 (0.50, 1.17) 0.93 (0.72, 1.07)
Additionally adjusted for creatinine and  
elevated %DMAs, MAs, iAs in urine
Dysglycemia
Diabetes 1.76 (1.03, 3.02)* 1.98 (1.12, 3.50)* 2.78 (1.55, 5.00)* 1.45 (1.19, 1.77)*
Prediabetes 0.89 (0.53, 1.51) 1.22 (0.72, 2.08) 1.16 (0.65, 2.04) 1.04 (0.86, 1.25)
Triglycerides ≥ 150 mg/dL 1.41 (0.95, 2.08)** 1.55 (1.04, 2.32)* 1.96 (1.28, 3.00)* 1.25 (1.08, 1.44)*
Cholesterol ≥ 200 mg/dL 1.25 (0.80, 1.96) 1.56 (0.98, 2.47)** 1.89 (1.16, 3.06)* 1.22 (1.04, 1.44)*
LDL ≥ 130 mg/dL 1.08 (0.65, 1.81) 1.42 (0.84, 2.40) 1.54 (0.88, 2.69) 1.16 (0.96, 1.40)
HDL < 40/50 mg/dL 0.92 (0.62, 1.36) 1.09 (0.73, 1.64) 0.81 (0.52, 1.25) 0.87 (0.77, 0.99)*
Hypertensionc 0.74 (0.48, 1.14) 0.73 (0.47, 1.14) 1.02 (0.64, 1.61) 1.03 (0.89, 1.20)
Results are derived from multinomial or logistic models adjusted for age, sex, education, smoking status, alcohol consump-
tion, recent seafood intake, weight status, elevated waist circumference, and main water source (well, treatment plant, 
or other); multinomial model used for diabetes and prediabetes versus neither; logistic models used for other outcomes. 
ln-Transformed urinary creatinine and > median %DMAs, MAs, and iAs in urine additionally included in models as indi-
cated.
aDiabetes: fasting plasma glucose (FPG) ≥ 126 mg/dL, 2-hr plasma glucose (2HPG) ≥ 200 mg/dL, or self-reported diabetes 
diagnosis or medication use. Prediabetes: FPG ≥ 110 to < 126 mg/dL or 2HPG ≥ 140 mg/dL. Normoglycemic individuals (i.e., 
individuals with no diabetes or prediabetes) are the referent. bLDL-cholesterol: estimated using the Friedewald equation if 
triglycerides < 400 mg/dL (Oliveira et al. 2013). cHypertension: SBP > 140, DBP > 90, or use of anti-hypertensive medication 
(medication use reported by 27.9% of hypertensive individuals). Normotensive individuals (no stage 1 or 2 hypertension) 
are the referent. *p < 0.05, **p < 0.10 for odds ratios for elevated vs. low cardiometabolic risk associated with increasing 
water As exposure vs. referent of < 27.5 μg/L (n = 273).
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in individuals not using anti-hypertensive 
medication: 1.19 (95% CI: –0.29, 2.66) 
p = 0.12 for SBP; 0.02 (95% CI: 0.88, 0.93) 
p = 0.95 for DBP].
iAs metabolism and CM risk markers. 
Higher %DMAs and DMAs/MAs in 
urine were associated with increased odds 
of diabetes, elevated TG, and hyperten-
sion (Figure 2). The relationships between 
these indicators and other CM outcomes 
were non-linear and weak. Conversely, an 
elevated %MAs was associated with reduced 
odds of diabetes, elevated TG, and hyperten-
sion. Similarly to %MAs, a high MAs/iAs 
ratio was negatively associated with diabetes. 
Associations of this ratio with other outcomes 
did not reach significance (p < 0.05), but in 
contrast to diabetes, such associations gener-
ally suggested weak increases in risk. A high 
%iAs was associated with reduced odds of 
elevated TG [adjusted OR for the highest vs. 
lowest quartiles: 0.58 (95% CI: 0.39, 1.86)]; 
other associations were weaker and were 
not significant.
iAs metabolism, iAs exposure, and 
CM risk markers. We also examined joint 
effects of iAs metabolism and iAs exposure 
to assess whether associations between 
CM risk markers and As in drinking 
water varied depending on profiles of iAs 
metabolites in urine. For subjects with high 
levels of exposure to water As, the odds of 
diabetes (Figure 3) and of elevated TG (see 
Supplemental Material, Table S3) were 
significantly increased when individuals had 
not only higher exposure but also elevated 
%DMAs in urine (interaction p < 0.10). 
For example, the adjusted OR for diabetes 
associated with being in the highest versus 
the lowest quartile of water As was 2.61 
(95% CI: 1.22, 5.57) for participants 
with elevated %DMAs, but it was 0.87 
(95% CI: 0.37, 2.04) for participants with 
low DMAs. Similarly, an elevated %DMAs 
increased the odds of elevated TG associ-
ated with elevated concentrations of urinary 
tAs (interaction p < 0.10; see Supplemental 
Material, Table S3). The adjusted OR for 
the association between the highest versus 
the lowest quartiles of water As and high TG 
was 3.31 (95% CI: 1.89, 5.78) versus 1.18 
(95% CI: 0.66, 2.08). Using continuous CM 
outcomes, among subjects without diabetes, 
the multivariable-adjusted mean increases in 
2HPG and triglycerides associated with water 
As were significantly larger when %DMAs 
was elevated (inter action p < 0.10) (see 
Supplemental Material, Table S2). Increases 
in mean FPG, 2HPG, and triglycerides asso-
ciated with elevated urinary tAs were also 
stronger among individuals with elevated 
%DMAs than among those with decreased 
%DMAs (inter action p < 0.10 for all) (see 
Supplemental Material, Table S2).
Discussion
In this study, both moderate exposure to As 
in drinking water and modest concentra-
tions of speciated urinary As were associated 
with several CM risk markers. Water As 
concentrations ≥ 25.5 μg/L were associated 
with increased odds of diabetes and elevated 
plasma TG and TC. Similar concentra-
tions of urinary tAs (≥ 27.1 μg/L) were also 
associated with diabetes and elevated TG, 
with higher levels (≥ 105.0 μg/L) associ-
ated with high TC. Although neither water 
As nor urinary tAs was associated with 
increased odds of prediabetes (Tables 2 and 
3), both were positively associated with 
increases in mean FPG and 2HPG among 
normo glycemic individuals (Figure 1). 
Unexpectedly, we found that iAs exposure 
was associated with decreased odds of low 
HDL. Associations with hypertension and 
blood pressure measures, or with LDL, were 
weak or null within the range of exposures in 
the present study.
When we used urinary As profiles to char-
acterize capacity to metabolize iAs, we found 
that an elevated %DMAs—or a decreased 
%MAs—was associated with increased odds 
of diabetes, elevated TG, and hypertension. 
Moreover, the increased odds of diabetes 
and elevated TG associated with increased 
concentrations of water As were stronger 
among individuals with an elevated %DMAs. 
This finding suggests that individuals with 
patterns of metabolism characterized by this 
Figure 2. Associations between urinary As metabolism indicators and cardiometabolic risk. Odds ratios 
(95% CIs) for elevated cardiometabolic risk associated with increasing quartiles of urinary iAs metabolism 
indicators from multinomial or logistic models adjusted for total speciated urinary arsenic, as well as 
age, sex, education, ethnicity, weight status, waist circumference, smoking status, alcohol consumption, 
recent seafood intake, and water source (well, treatment plant, or other). n = 1,090 Adults. Cardiometabolic 
markers: DM, diabetes mellitus; HDL, high-density lipoprotein cholesterol; HTN, hypertension; LDL, 
low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides. Urinary As indicators: DMAs, 
dimethylarsenic; iAs, inorganic As; MAs, methylarsenic. Cardiometabolic outcomes defined as follows: 
DM, fasting plasma glucose ≥ 126 mg/dL, 2-hr plasma glucose ≥ 200 mg/dL, or self-reported diabetes diag-
nosis or medication use; elevated TC ≥ 200 mg/dL; elevated TG ≥ 200 mg/dL; elevated LDL ≥ 130 mg/dL; low 
HDL = < 40 mg/dL; hypertension SBP > 140 mmHg, DBP > 90 mmHg or anti-hypertensive medication use. 
Quartile markers (1st = referent): 2nd, black diamond; 3rd, white square; 4th, blue circle. Quartile cutoffs 
for urinary As metabolism indicators defined as follows: (A) %DMAs = < 70.65, 70.65 to < 76.78, 76.78 to 
< 81.52, ≥ 81.52; (B) %MAs = < 10.90, 10.90 to < 14.0, 14.0 to < 17.66, ≥ 17.66; (C) DMAs/MAs = < 4.05, 4.05 to 
< 5.47, 5.49 to < 7.38, ≥ 7.38; (D) MAs/iAs = < 1.185, 1.185 to < 1.576, 1.576 to < 2.11, ≥ 2.11; (E) %iAs = < 6.389, 
6.389 to < 8.873, 8.873 to < 12.270, ≥ 12.270.
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marker may have increased susceptibility to 
adverse health outcomes associated with As 
exposure. Similarly, for urinary tAs, indi-
viduals with an elevated %DMAs had signifi-
cantly higher mean increases in fasting and 
2-hr glucose, and fasting TG and TC than 
individuals with decreased %DMAs.
Elevated %DMAs and decreased %MAs, 
as well as elevated DMAs/MAs and MAs/iAs 
ratios, have been proposed as indicators of 
efficient enzymatic methylation of iAs 
(Del Razo et al. 1997; Tseng 2007). Several 
studies in settings with high iAs exposure 
have reported a high %MAs to be associated 
with markers of increased CM risk (Chen 
et al. 2013a, 2013b; Li et al. 2013a). Results 
from our independent population-based 
study in the Zimapán and Lagunera regions 
of Mexico suggest that the positive associa-
tion with urinary DMAs species may be at 
least partly attributable to elevated urinary 
concentrations of the toxic trivalent form 
of DMAs, DMAsIII (Del Razo et al. 2011). 
Notably, consistent with our findings, several 
recent studies also found a high DMAs/MAs 
ratio, a high %DMAs, or a decreased %MAs 
in urine to be associated with an increased 
risk of diabetes, metabolic syndrome, or indi-
vidual CM risk markers (Chen et al. 2012; 
Del Razo et al. 2011; Kim et al. 2013; Moon 
et al. 2013; Nizam et al. 2013). Additional 
research is needed to assess the extent to 
which the toxic trivalent metabolites DMAsIII 
and MAsIII may influence CM risk associ-
ated with iAs exposure (Calatayud et al. 2014; 
Navas-Acien et al. 2006; Stýblo et al. 2002).
In line with our findings, several recent 
prospective studies have found varying 
levels of iAs exposure—including median 
urinary As concentrations ≤ 20 μg/L as 
well as > 200 μg/L—to be associated with 
increased morbidity and mortality from CVD 
outcomes, including ischemic heart disease, 
stroke, and diabetes (Chen et al. 2011, 
2013b; James et al. 2013; Kim et al. 2013; 
Moon et al. 2012, 2013; Navas-Acien et al. 
2008, 2009). Previous cross-sectional studies 
in settings with high levels of As exposure 
reported elevated levels of As in water or hair 
to be associated not only with elevated TC, 
TG, and fasting glucose but also with elevated 
LDL, decreased HDL, elevations in both SBP 
and DBP, and systemic inflammation (Chen 
et al. 2012; Karim et al. 2013; Wang et al. 
2007). These studies suggest the possibility 
of additional or more severe CM effects at 
higher levels of exposure.
The present study found a high propor-
tion of DMAs to be associated with hyper-
tension. However, the associations between 
iAs exposure and hypertension were weak 
and were not significant, perhaps in part 
due to the moderate exposure levels. 
Notably, associations with hypertension 
have been heterogeneous in areas with 
water As < 400 μg/L, albeit consistent at 
higher levels of exposure (Abhyankar et al. 
2012; Islam et al. 2012; Jones et al. 2011). 
Normalizing versus adjusting for creatinine 
slightly strengthened the associations with 
urinary As; however, studies reporting asso-
ciations with hypertension using this metric 
(Li et al. 2013b) have also had considerably 
higher exposures than those in this popula-
tion: median 136 μg versus 47.4 μg As/g 
creatinine. Future research should assess 
whether moderate exposure may be more 
closely linked to alternative indicators of 
vascular function (Kunrath et al. 2013; Li 
et al. 2013b; Wu et al. 2012) or may vary 
in genetically or nutritionally vulnerable 
subgroups with varying iAs metabolism 
(Chen et al. 2007).
Despite increases in mean 2HPG and 
FPG associated with iAs exposure among 
normoglycemic individuals (Figure 1), iAs 
exposure was not associated with prediabetes. 
It is possible that the cutoffs used to charac-
terize prediabetes were not sufficiently sensi-
tive in our population, that iAs exposure may 
promote rapid progression to more severe 
disease, or that associations with glucose 
measurements are not causal.
Although additional prospective studies 
are needed to evaluate these relationships, 
laboratory studies suggest that iAs or its 
metabolites may inhibit insulin secretion 
or signaling (Douillet et al. 2013; Fu et al. 
2010; Paul et al. 2007), alter lipid metabo-
lism (Cheng et al. 2011; Hossain et al. 2013; 
Muthumani and Prabu 2014), and generate 
proinflammatory responses (Calatayud et al. 
2014; Druwe et al. 2012). Increases in TC, 
LDL, and TG—along with decreases in 
HDL—have been observed in rodents treated 
with iAs (Muthumani and Prabu 2014), in 
addition to increases in hypertension, cardiac 
hypertrophy, and atherosclerosis (Cheng et al. 
2011; Lemaire et al. 2011; Sanchez-Soria et al. 
2012). The unexpected association with HDL 
requires further study in diverse populations 
and in laboratory settings. It is important to 
note that large disparities in the prevalence, 
predictors, and health consequences of low 
HDL have been described in Mexican and 
other Hispanic populations compared with 
populations of European descent (Aguilar-
Salinas et al. 2001; Morales et al. 2014; 
Paramsothy et al. 2010; Salas et al. 2014).
Despite the limitations inherent in a 
cross-sectional design, the findings from this 
study are largely consistent with those from 
experimental research and from several smaller 
epidemiological studies in high-exposure 
settings. Moreover, although personal 
exposure was characterized on the basis of a 
single urine sample, the findings for water As 
and urinary tAs were largely consistent. Few 
previous studies have provided comparisons 
of urinary and water As measures or have 
used urinary indicators to assess how metabo-
lism may modify the health effects of envi-
ronmental exposure through drinking water 
contaminated by As (Chen et al. 2013a, 
2013b). The consistency of unadjusted and 
multivariable-adjusted results, as well as those 
of sensitivity analyses excluding individuals 
previously diagnosed with hypertension or 
diabetes who may have adjusted behaviors 
such as water consumption, also supports the 
possibility of a causal relationship. Moreover, 
the close resemblance of the high prevalence 
Figure 3. Water As and odds of prevalent diabetes in subjects with vs. without elevated % urinary DMAs. 
ORs (95% CIs) for prevalent diabetes associated with household water As categories (< 25, 25 to < 50, 50 
to < 100, and ≥ 100 μg/L) in subjects with proportions of DMAs defined as low versus high based on the 
median of 76.6%. The referent group for all ORs is subjects with %DMAs below the median in the lowest 
quartile of water As. The results are derived from multinomial models adjusted for age, sex, smoking 
status, alcohol consumption, BMI, elevated waist circumference, and main water source (well, treatment 
plant, or other). 
*p < 0.10 for additive interaction (relative excess risk for interaction) for the joint effect of water As and high %DMAs. 
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of obesity and cardiometabolic risk reported 
herein to that reported for the general popula-
tion of Mexico (Barquera et al. 2009; Salas 
et al. 2014; Villalpando et al. 2010) does not 
suggest selectivity in our cohort with respect to 
these outcomes. Studies in such settings may 
help provide a more complete understanding 
of how iAs exposure may influence cardio-
metabolic risk because many previous studies 
of these relationships have been conducted in 
settings such as Bangladesh, where the preva-
lence of obesity and CM disorders is relatively 
low (Chen et al. 2013b; Pan et al. 2013).
Conclusion
In summary, the results of this study fill a gap 
in current knowledge by suggesting potential 
CM risks associated with chronic exposure 
to As at levels < 100 μg/L in drinking water 
(Maull et al. 2012; Moon et al. 2013). 
Associations with measurements of dyslipid-
emia, which have been infrequently studied 
to date, warrant further study, given that the 
implications of our results for health risks were 
inconsistent for HDL, LDL, and triglycer-
ides. Studies that incorporate measurements 
of specific lipid fractions and particles may be 
better able to evaluate the health risks of any 
association with iAs exposure (Genest 2008; 
Vickers and Remaley 2014). Our findings also 
suggest that iAs metabolism may influence the 
extent to which environmental exposure to iAs 
adversely affects the risk of CM impairment. 
Studies that measure trivalent and pentavalent 
urinary As species are needed to better under-
stand the impact of metabolism on the health 
risks associated with iAs exposure.
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